- Home
- FORA vs TLSA Comparison
FORA vs TLSA Comparison
Compare FORA & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FORA
- TLSA
- Stock Information
- Founded
- FORA 2014
- TLSA 2013
- Country
- FORA United States
- TLSA United Kingdom
- Employees
- FORA N/A
- TLSA N/A
- Industry
- FORA Computer Software: Prepackaged Software
- TLSA Biotechnology: Pharmaceutical Preparations
- Sector
- FORA Technology
- TLSA Health Care
- Exchange
- FORA Nasdaq
- TLSA Nasdaq
- Market Cap
- FORA 63.8M
- TLSA 87.8M
- IPO Year
- FORA N/A
- TLSA 2000
- Fundamental
- Price
- FORA $2.10
- TLSA $1.20
- Analyst Decision
- FORA Strong Buy
- TLSA
- Analyst Count
- FORA 1
- TLSA 0
- Target Price
- FORA $5.00
- TLSA N/A
- AVG Volume (30 Days)
- FORA 14.2K
- TLSA 145.8K
- Earning Date
- FORA 11-07-2024
- TLSA 05-10-2024
- Dividend Yield
- FORA N/A
- TLSA N/A
- EPS Growth
- FORA N/A
- TLSA N/A
- EPS
- FORA 0.06
- TLSA N/A
- Revenue
- FORA $20,371,880.00
- TLSA N/A
- Revenue This Year
- FORA N/A
- TLSA N/A
- Revenue Next Year
- FORA $10.64
- TLSA N/A
- P/E Ratio
- FORA $36.34
- TLSA N/A
- Revenue Growth
- FORA 6.97
- TLSA N/A
- 52 Week Low
- FORA $2.00
- TLSA $0.41
- 52 Week High
- FORA $4.15
- TLSA $1.74
- Technical
- Relative Strength Index (RSI)
- FORA 38.13
- TLSA 65.44
- Support Level
- FORA $2.05
- TLSA $0.83
- Resistance Level
- FORA $2.16
- TLSA $0.92
- Average True Range (ATR)
- FORA 0.05
- TLSA 0.09
- MACD
- FORA 0.00
- TLSA 0.03
- Stochastic Oscillator
- FORA 31.77
- TLSA 84.52
About FORA Forian Inc.
Forian Inc provides a suite of Software, data management capabilities, and proprietary data and analytics to optimize and measure operational, clinical, and financial performance for customers within the traditional and emerging life sciences, healthcare payer, and provider segments, as well as cannabis dispensaries, manufacturers, and cultivators.
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.